Should Investors Expect More Delays at Solazyme in 2014?

Industrial biotech and renewable oils company Solazyme (NASDAQ: TVIA  ) hit investors with some surprising news when it reported third-quarter earnings. Management revised its 2013 guidance for total revenue downward by 25% and announced that its commercial scale facility being built in Moema, Brazil, with sugarcane supplier Bunge (NYSE: BG  ) would no longer begin operations in the fourth quarter after installing advanced quality control equipment. Instead, the facility will come online during the first quarter along with a commercial scale facility in Clinton, Iowa, being retrofitted with agricultural giant Archer Daniels Midland (NYSE: ADM  ) . The move should reduce risk in the long term for investors, but the market wasn't very happy.

SZYM Chart

SZYM data by YCharts.

There were several sound reasons for shares to sink. Lower guidance was an obvious candidate, while investors were also reminded about the reality of share dilution now and in the future. But perhaps the biggest reason for caution was the uncertainty associated with production -- and therefore product revenue -- in 2014, which will be heavily aggregated in the second half of the year. Encountering even one setback during ramp up could have a detrimental effect on shares. Should it be a real concern for investors?

Where to focus on scale-up
Investors may be thinking that production will go smoothly in 2014 due to the simple fact that Solazyme has successfully demonstrated that its microbes behave in 500,000 liter fermenters, which will be utilized at Clinton and Moema. That represents a sizable improvement over the 128,000 liter fermenters used to date at its Peoria demonstration facility and an enormous improvement over previous volumes, although the company has yet to prove all production metrics at 500,000 liter scale and still needs to move to 625,000 liter fermenters to achieve its goals.

Additionally, focusing on scale-up in terms of individual tank volumes is a little outdated at this point in development. For instance, consider that moving from 128,000 liter fermenters to 500,000 liter fermenters is a fourfold increase in volume. That's nothing to sneeze at, but if we zoom out and focus on the entire biorefinery, we find that tank volumes mean little without optimized process scheduling.

What the heck is process scheduling? It's the term applied to the utilization and interdependence of all equipment involved in a given process. Engineers must be able to successfully handle and coordinate not just what occurs inside of a fermenter, but also what occurs before nutrients and microbes are added (upstream), what occurs during purification and separation (downstream), how quickly every task is completed, and maintain and clean all of the holding tanks and piping that make it possible. It seems a bit silly to focus on tank volumes when you consider the big picture.

Now, you don't have to be an engineer to see that (partially) proving 500,000 liter fermenters doesn't ensure smooth sailing for 2014. Consider that Solazyme's current facility in Peoria has an annual nameplate capacity of 1,820 metric tons. Moema and Clinton will have annual nameplate capacities of 100,000 MT and 20,000 MT, respectively. That roughly translates to a 55-fold and an 11-fold scale-up in process scheduling -- volumes of nutrients, buffers, cleaning agents, and the like -- respectively. That's a big leap that could lead to any number of potential setbacks and delays. 

Not the bogeyman
The leap in process scheduling isn't meant to be the bogeyman for investors. In all fairness, Solazyme has designed the engineering solutions to handle the process scheduling of its commercial scale facilities in Moema and Clinton. Additionally, the company will be easing into commercial operations over the 12- to 18-month ramping period for each facility to work out unforeseen kinks in its process scheduling plans. 

Source: Solazyme 3Q13 earnings presentation.

Essentially, downtime is built into ramp-up. That doesn't mean delays won't happen, however. Problems will inevitably occur and it only takes one lingering obstacle to turn scheduled downtime into unscheduled downtime (i.e. a delay). Remember, Moema and Clinton represent the first time Solazyme will gain experience with its platform at commercial scale. There is no blueprint to follow.

Foolish bottom line
There's an old saying among process engineers: "Scale-up is more art than science." That simple and powerful phrase conveys the difficultly and unpredictability of process scale-up. Similar problems encountered at other industrial biotech companies should do the same. So while it's possible that Solazyme cruises through 2014 without any production setbacks, I don't think that's where investors or Wall Street should set the bar. I think it's best to prepare for additional delays.

Is industrial biotech too risky for you?
Depending on your investing style, the industrial biotech industry may represent an enormous opportunity or headache. Either way, opportunities to get wealthy from a single investment don't come around often, but they do exist, and our chief technology officer believes he's found one. In this free report, Jeremy Phillips shares the single company that he believes could transform not only your portfolio, but your entire life. To learn the identity of this stock for free and see why Jeremy is putting more than $100,000 of his own money into it, all you have to do is click here now.

Read/Post Comments (4) | Recommend This Article (5)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On December 13, 2013, at 3:32 AM, prginww wrote:

    It's pathetically deceitful how Motley Fool hypes a stock by claiming to invest $192,197 of their personal money into a company that is suppose to be the next big thing. At first, leading the reader to believe the "secret stock" will be revealed for free, only to find out you need to pay for a subscription at the end of a long, time consuming video or article.

  • Report this Comment On December 15, 2013, at 5:19 PM, prginww wrote:

    Max, OT - but would like your thoughts on this recent mblx patent. Would seem to seriously challenge current 1-4 BDO production paradigms (among other things). US 20130288317 A1. Specifically table 3. Near as I can tell, the g/g yield is on a glucose basis.

    email reply to

    (it's a zero, not an "o")


  • Report this Comment On December 15, 2013, at 5:45 PM, prginww wrote:

    Max, OT - I'd like your thoughts on a recent mblx patent US 20130288317 A1, specifically Table 3. It would seem to challenge current 1-4 BDO production paradigms among other things.

  • Report this Comment On December 15, 2013, at 11:12 PM, prginww wrote:

    Idiotic. clearly the upstream feed timing and learning how to clean the pipes is of no concern to a team that has already proven the ability to tailor the oils and been running the peoria facility already for some time. "In all fairness" your motivations are thinly veiled here Maxx! What Community College did you earn the BFA in Bioprocess Engineering? Did you get your industrial process experience with the easy-bake oven? I love it when some kid quotes old timers as though he understands, and owns, what decades of experience has taught them.

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2760346, ~/Articles/ArticleHandler.aspx, 9/29/2016 10:02:01 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 46 minutes ago Sponsored by:
DOW 18,143.45 -195.79 -1.07%
S&P 500 2,151.13 -20.24 -0.93%
NASD 5,269.15 -49.39 -0.93%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/29/2016 4:00 PM
TVIA $2.70 Down -0.03 -1.10%
TerraVia CAPS Rating: ***
ADM $41.53 Down -0.32 -0.76%
Archer Daniels Mid… CAPS Rating: ****
BG $58.76 Down -0.72 -1.21%
Bunge CAPS Rating: ***